2023 World Conference on Lung Cancer (Posters)-EP13.07. Efficacy and Safety of Antiangiogenic Therapy plus Immunotherapy as Later-line Treatment for Small Cell Lung Cancer

EP13.07. Efficacy and Safety of Antiangiogenic Therapy plus Immunotherapy as Later-line Treatment for Small Cell Lung Cancer - PDF(Slides)

Back to course

Pdf Summary

This study aimed to investigate the efficacy and safety of anti-angiogenic therapy combined with immune checkpoint inhibitors (ICIs) versus anti-angiogenic monotherapy as second or later-line treatment for small cell lung cancer (SCLC). Medical records and follow-up data from SCLC patients who received either combination therapy or monotherapy were retrospectively collected and analyzed. The primary endpoint was progression-free survival (PFS), with secondary endpoints including overall survival (OS), objective response rate (ORR), disease control rate (DCR), and adverse reactions (AEs).<br /><br />The results showed that patients in the combination therapy group had a longer PFS compared to the monotherapy group. Both univariate and multivariate regression analyses demonstrated that combination therapy was a significant protective factor against disease progression. Female gender and no prior immunotherapy showed a decreasing trend in the risk of disease progression. The combination group also had a better DCR than the monotherapy group, with no significant difference in the incidence of AEs between the two groups.<br /><br />Overall, ICIs combined with anti-angiogenic therapy demonstrated superiority in disease control and delayed progression over anti-angiogenic monotherapy as later-line treatment for SCLC. The study included a total of 52 patients, with the combination therapy group comprising 33 patients and the monotherapy group comprising 19 patients.<br /><br />In conclusion, this study provides evidence supporting the use of combination therapy with anti-angiogenic agents and ICIs as a later-line treatment option for SCLC patients. This treatment approach resulted in improved disease control and prolonged progression-free survival compared to anti-angiogenic monotherapy.

Asset Subtitle

Yutao Liu

Meta Tag

Speaker Yutao Liu

Topic SCLC & Neuroendocrine Tumors: Relapse & Salvage Therapy

Keywords

anti-angiogenic therapy

immune checkpoint inhibitors

small cell lung cancer

combination therapy

monotherapy

progression-free survival

overall survival

objective response rate

disease control rate

adverse reactions